What s New in Advanced Disease (CRPC)?

Size: px

Start display at page:

Download "What s New in Advanced Disease (CRPC)?"

Pierce Morris
5 years ago
Views:

1 What s New in Advanced Disease (castration resistant prostate cancer = CRC)? Matthew Rettig, MD Associate rofessor Department of Medicine Division of Hematology-Oncology Department of Urology Medical Director, rostate Cancer rogram Institute of Urologic Oncology David Geffen School of Medicine at UCLA Novel/Emerging Therapies Differentiating Agents HDAC inhibitors (vorinostat) Immunotherapies Sipuleucel (rovenge), ipilimumab (anti-ctla4) Gene Therapy Virus Based Induce death, Enzyme/rodrug, replace defective genes Targeting Aberrant Cell Signaling ZD4054, oblimersen, etc Angiogenesis Avastin, Aflibercept, Thalidomide targeting agents MDV3100 Abiraterone Hedgehog inhibitor Clinical States of rostate Cancer Non-metastatic, hormone dependent Non-metastatic, castration resistant Clinically localized SA recurrence Metastatic, hormone dependent Metastatic, castration resistant Death from prostate cancer Death from non-prostate cancer illness years ERSECTIVES IN UROLOGY: OINT- COUNTEROINT November 5 7, 2009 The Scottsdale laza Scottsdale, Arizona 15.1

best friends, elderly male dogs. First recognition of CRC.

2 Huggins and Hormone Therapy Charles Huggins, M.D. ( ) We wanted to see if hormone therapy would do for elderly gentlemen what it would do for their best friends, elderly male dogs. First recognition of CRC. Working Mechanism 5 -reductase DHT HS T lasma membrane HS cytoplasm coactivators nucleus roliferation Survival SA E 15.2 ERSECTIVES IN UROLOGY: OINT- COUNTEROINT November 5 7, 2009 The Scottsdale laza Scottsdale, Arizona

3 Hypothalamus LHRH ituitary LH Testes T rostate LHRH analogue Leuprolide Goserelin ACTH Adrenals DHEA T antagonists Bicalutamide Flutamide Nilutamide 5 -reductase 1 5 -reductase 2 5 -reductase inhibitors Finasteride Dutasteride DHT roliferation Survival Angiogenesis SA CRC as the referred Terminology The terms androgen-independent prostate cancer (AIC) and hormone refractory prostate cancer (HRC) imply that additional hormonal manipulations will be ineffective, yet secondary and tertiary hormonal therapies may be effective. CRC indicates some measure of progression of disease (i.e. biochemical, clinical or radiographic) despite castrate levels of circulating androgens. Current Management of Metastatic CRC Median survival is months. Secondary and tertiary hormonal manipulations are reasonable options: Stop antagonist and observe for withdrawal response. Switch antagonist. (e.g. flutamide bicalutamide). Initiate ketoconazole. Estrogens: high CV risk. SA response rates from 20-60%. No established survival benefit. alliative management: Spot radiation radionuclide therapy samarium 153 strontium 89 Bisphosphonates (zoledronate) Current Management of Metastatic CRC Docetael-based chemotherapy is the only treatment that has been established to etend life epectancy in patients with metastatic CRC. etends median survival by 2-3 months. 1,2 Well-tolerated and can be given irrespective of age. 1 NEJM 351:1502, NEJM 351:1513, 2004 ERSECTIVES IN UROLOGY: OINT- COUNTEROINT November 5 7, 2009 The Scottsdale laza Scottsdale, Arizona 15.3

4 Mechanisms of Castration Resistance 1. -dependent 2. -independent Mechanisms Giving Rise to CRC -dependent athway: Sustained activation -independent athway Hypersensitive T (castrate levels) romiscuous Corticosteroids rogesterone Flutamide Outlaw Growth Factors DHT RTK AKT MAK coactivators Target Genes E roliferation Survival SA Epression in CRC Clin Can Res 10:440, ERSECTIVES IN UROLOGY: OINT- COUNTEROINT November 5 7, 2009 The Scottsdale laza Scottsdale, Arizona

Intracellular Androgen Levels in CRC = benign = CRC CRC = 2.78 nm Benign = 3.21 nm p = 0.

00001 Activation of transcriptional activity by androgens Can Res 64:765, 2004.

benign primary C CRC BM mets 17 Hydroylase control Ig control Ig control Ig CRC in prostate CRC

5 Intracellular Androgen Levels in CRC = benign = CRC CRC = 2.78 nm Benign = 3.21 nm p = 0.21 Clin Can Res 10:440, Can Res 64:765, CRC = 1.45 nm Benign = 8.13 nm p < Activation of transcriptional activity by androgens Can Res 64:765, Biosynthesis of Androgens CRC cells activate the androgen synthesis enzymatic pathway. benign primary C CRC BM mets 17 Hydroylase control Ig control Ig control Ig CRC in prostate CRC soft tissue met Cancer Res 66:2815, ERSECTIVES IN UROLOGY: OINT- COUNTEROINT November 5 7, 2009 The Scottsdale laza Scottsdale, Arizona 15.5

Biosynthesis of Androgens ketoconazole Adrenals CRC Testis Hypersensitive T (castrate levels) T MDV3100 romiscuous Corticosteroids rogesterone Flutamide Outlaw Growth Factors RTK abiraterone AKT MAK

6 Biosynthesis of Androgens ketoconazole Adrenals CRC Testis Hypersensitive T (castrate levels) T MDV3100 romiscuous Corticosteroids rogesterone Flutamide Outlaw Growth Factors RTK abiraterone AKT MAK coactivators Target Genes E roliferation Survival SA Inhibition Androgen roduction Abiraterone 15.6 ERSECTIVES IN UROLOGY: OINT- COUNTEROINT November 5 7, 2009 The Scottsdale laza Scottsdale, Arizona

7 Abiraterone hase 2 CRC: Chemo-Naive 27/44 (61%) have durable SA declines 50%. 11/44 (25%) had 90% SA decline. 21 patients with measurable disease. 14/21 pts with objective partial response. 7/21 pts with stable disease > 3 months. Abiraterone hase 2 CRC: ost-docetael 14/28 patients with 50% SA decline. Median time to SA progession ~ 6 months. 4/18 pts with measurable disease had R. hase 3 Study of Abiraterone: (post-chemotherapy metastatic CRC) Multinational, phase 3, placebo-controlled, double-blind study in patients with metastatic CRC with progression after docetael-based chemotherapy. 175 centers, 1158 patients. Randomization allocation 2:1. (abiraterone:placebo). All patients receive prednisone 5 mg po bid. rimary endpoint = Overall Survival. Accrual completed. hase 3 Study of Abiraterone: (pre-chemotherapy metastatic CRC) Multinational, phase 3, placebo-controlled, double-blind study in asymptomatic or minimally symptomatic patients with metastatic CRC who are chemotherapy naive. rimary endpoint = rogression-free Survival. First patient enrolled in ERSECTIVES IN UROLOGY: OINT- COUNTEROINT November 5 7, 2009 The Scottsdale laza Scottsdale, Arizona 15.7

MDV3100: hase 1-2 results 22/30 have SA response, 12 of which were > 50% decline. hase 3 has enrolled first patient in 9/09. Science 324:787, 2009.

8 MDV3100: hase 1-2 results 22/30 have SA response, 12 of which were > 50% decline. hase 3 has enrolled first patient in 9/09. Science 324:787, A Cautionary Note NH 2- NLS (617-34) TAD DBD LBD -COOH NLS (617-34) LBD NH 2- TAD DBD -COOH Ligand-independent transcriptional activity J.Steroid Biochem Mol Biol. 41: , Cancer Res. 67:2007, Cancer Res. 68:5469, Cancer Res. 69:16, Conclusions, Take Home Messages, and Other Comments CRC is a lethal event. The represents a viable molecular target in at least a subset of CRCs. However, the biochemical and molecular events that lead to castration resistance are etremely comple and a simple therapeutic agent is not apt to be effective in all or perhaps even most cases. Innumerable drugs are in various stages of pre-clinical and clinical development, and incremental advances are anticipated. Major advances will require the identification and targeting of sentinel growth promoting molecular events ERSECTIVES IN UROLOGY: OINT- COUNTEROINT November 5 7, 2009 The Scottsdale laza Scottsdale, Arizona

New Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일

New Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일 Castrate-Resistant Prostate Cancer (CRPC) Current standard therapy Androgen receptor (AR) in CRPC New systemic therapies Hormonal therapy